Follow @TheHPRA
Contact us
As Gaeilge
My HPRA:
Login
Register
About Us
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Medicines
Safety Notices
My HPRA:
Login
Register
About Us
Medicines
COVID-19 vaccines and treatments
Our Role
Medicines Information
Safety Information
Safety Notices
Quality Information
Regulatory Information
News & Events
Special Topics
Emergency Medicines
Emergency Contact Details
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Revlimid (lenalidomide) - Important Safety Information from Celgene as approved by the Irish Medicines Board 11.02.2011
Notice type:
3rd Party Publications
Date:
11/02/2011
Problem Or Issue:
Important safety information communication from the Health Products Regulatory Authority on the association of Revlimid (lenalidomide) with venous and arterial thromboembolic events.
Important Safety Information communication from Celgene
« Back
Date Printed: 04/05/2024